Patent lineage & manufacturing authority

Where it comes from.

Cetosome® technology is not a marketing term. It is a granted patent family with defined composition ratios, measured particle physics and real-time stability data.

01 Patent lineage

Two patents, one platform

Answer first

The platform rests on two US patents assigned to Cymbiotics, Inc. US 8,394,759 B2 (granted 2013) established cetylated fatty ester penetrant complexes for transdermal delivery. US 9,084,818 B2 (granted 2015) defined self-assembling cetosome nanoparticles, with claimed composition ratios and a zeta potential of −20 to −100 mV.

US 8,394,759 B2 · granted 12 Mar 2013

Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Inventors
Raj R. Barathur; Jack Bain Bookout
Assignee
Cymbiotics, Inc.
Priority
2008-11-21
Core teaching
4–20% cetylated fatty ester penetrant group with polar solvents and antioxidant in a carrier base
Status
Listed as expired (fee-related) by Google Patents; teaching incorporated into US 9,084,818 B2
Full text ↗[1]

US 9,084,818 B2 · granted 21 Jul 2015

Topical dermal delivery compositions using self assembling nanoparticles with cetylated components

Inventors
Raj R. Barathur; Jack Bain Bookout
Assignee
Cymbiotics, Inc., Escondido, CA
Claim 1
≥40% water; 4–20% of ≥4 cetylated/stearyl esters; alcohols ≥1:3; 1–20% surfactant; 2–30% polar solvent; ζ −20 to −100 mV
Particle size
60–850 nm measured · 30 nm–5 µm claimed
Status
Active per Google Patents; anticipated expiry 2033-02-15
Patent PDF ↗[2]
  1. Priority dateCetylated fatty ester penetrant complexes (later US 8,394,759 B2)
  2. Application filedUS 12/608,963, Barathur & Bookout
  3. Application filedUS 13/767,886, self-assembling nanoparticles with cetylated components
  4. GrantedUS 8,394,759 B2
  5. PublishedUS 2014/0234428 A1, the 'cetosome' application cited by clinical papers
  6. GrantedUS 9,084,818 B2, claim 1 specifies ζ −20 to −100 mV
  7. Peer-reviewed clinical dataTwo Cureus studies of cetosomal 5% minoxidil (n = 261; n = 80)
  8. Anticipated expiryUS 9,084,818 B2 (per Google Patents; not a legal conclusion)

02 Stability validation

Measured, not asserted

Answer first

The patent reports particle size, zeta potential and conductivity for three batches of each composition, each tested in triplicate on a Zetasizer Nano ZS. Real-time stability at 25 °C and 65% relative humidity was established for up to 26 months, with stability parameters including nanoparticle integrity and active (analyte) concentration.

CompositionParticle diameter (nm, mean ± SE)Zeta potential (mV)Stability established
CLDC070482.6 ± 15.8 / 845.7 ± 114.4−49.2 ± 1.226 months real-time (25 °C / 65% RH)
DPNC100895.8 ± 52.5 / 258.0 ± 68.8−40.2 ± 2.46 months real-time and 40 °C / 75% RH
RDNC1209602.8 ± 4.8−22.3 ± 6.318 months real-time (25 °C / 65% RH)

Source: US 9,084,818 B2, Table 3[2]. Interpreting zeta potential and DLS data[5].

03 Origin & manufacturing

From Cymbiotics R&D to the dermatology clinic

Answer first

Cymbiotics, Inc., a pharmaceutical research company in Escondido, California, originated Cetosome® technology and holds its patents as assignee. It licenses the platform to formulation and manufacturing partners. In India, the technology reaches patients through prescription pharmaceutical brands and through a dedicated consumer-facing clinical skincare line.

01 · Origin

Cymbiotics, Inc.

Pharmaceutical R&D originator and patent assignee. Licensor of the platform, which is designed for both dermal and transdermal delivery.

02 · Validation

Clinical literature

Peer-reviewed tolerability data for cetosomal formulations (2023), published in Cureus and indexed in PubMed.[3][4]

03 · Clinical line

Monoskin

The consumer-facing dermatological range built on the Cetosome® platform, dispensed through clinics and at monoskin.com.

Editorial standards

Who writes and reviews this site

Formulation Chemistry Desk

In-house desk responsible for the biophysical, formulation and literature content on cetosomes.com.

Dermal Delivery & Pharmaceutical R&D Panel

Technical review panel that checks every page against primary patent text and peer-reviewed literature before publication and on each update.

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Corrections: if you find an error, message the formulation desk; corrected pages show a new peer-updated date.

Frequently asked

Who invented Cetosome® technology?

Cetosome® technology originates from Cymbiotics, Inc. (Escondido, California). The inventors named on the patents are Raj R. Barathur and Jack Bain Bookout. The core nanoparticle patent is US 9,084,818 B2, granted 21 July 2015.

Is the Cetosome® patent still active?

Google Patents lists US 9,084,818 B2 as active, with an anticipated expiration of 15 February 2033; that status is an assumption, not a legal conclusion. The earlier US 8,394,759 B2 is listed as expired for non-payment of fees. Its teaching is incorporated by reference into the later patent.


References

  1. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
  2. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  3. Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).
  4. Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
  5. Bhattacharjee S. DLS and zeta potential — What they are and what they are not?. Journal of Controlled Release 235:337–351. 2016.DOI 10.1016/j.jconrel.2016.06.017

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.

In your routine or your clinic

Explore Cetosome® formulations

Cetosome® vehicles are dispensed through dermatology, not mass retail. The direct way to bring the technology into your routine or practice is Monoskin, the dermatological range built on the platform.

For your skin: choose a need

For your clinic

Stocking or prescribing Cetosome® formulations? Reach the clinic team, or ask our formulation desk for the literature dossier.

Opens monoskin.com in a new tab. Diagnosis and the choice of active belong to your dermatologist.